The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Biocorp will receive an initial milestone payment this year
Proposed combination enhances Pfizer’s position as a leading company in oncology
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
Smart-performance, fully biodegradable biopolymer sourced from renewable raw materials
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
Subscribe To Our Newsletter & Stay Updated
